Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products

Next Previous
Trial Profile

A Phase 1 Study to Assess the Safety, Tolerability and Effectiveness of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver in the Reduction of Biochemical Markers and Symptoms Caused by Secretory Products

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rose bengal sodium (Primary)
  • Indications Colorectal cancer; Liver metastases; Neuroendocrine tumours; Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Provectus Biopharmaceuticals

    • Most Recent Events

    • 07 Feb 2023 Planned End Date changed from 1 May 2021 to 1 Sep 2023.
    • 21 Sep 2021 Results assessing intralesional (IL) PV-10, an autolytic immunotherapy that may elicit a disease-specific functional adaptive immune response in metastatic neuroendocrine neoplasms, presented at the 46th European Society for Medical Oncology Congress.
    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top